- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03729622
Carbohydrate Reduction and Impact on Gastrointestinal System (CRAIGS)
A Pilot Randomised Controlled Trial of the Effect of a Diet Low in Poorly Digested Carbohydrates on Gastrointestinal Form and Symptoms in Irritable Bowel Syndrome Patients
Title :
A pilot single blind randomised controlled trial of the effect of a diet low in poorly digested carbohydrates on gastrointestinal form and symptoms in irritable bowel syndrome patients
Acronym: CRAIGS
Short title: Carbohydrate reduction and impact on gastrointestinal system Chief Investigator: Prof Robin Spiller
Objectives:
The purpose of this study is to:
- Investigate the proportion of patients with Irritable Bowel Syndrome who report moderate or substantial improvement in their symptoms after 2 weeks of following a diet low in Fermentable Oligo-Di-Monosaccharides and Polyols (FODMAPs) compared to patients who are on their habitual diet.
- Determine the difference in colonic volume of IBS patients receiving immediate low FODMAP dietary intervention after 2 weeks compared to patients who are not on the diet (delayed dietary intervention).
- Investigate the changes in self-reported food intolerance that occurs before dietary intervention.
Trial Configuration:
2-arm, parallel group, randomised, controlled trial
Setting :
Research clinic within NIHR Biomedical Research Unit, Secondary care
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
TRIAL / STUDY OBJECTIVES AND PURPOSE
The trial aims to investigate the effect of a diet low in FODMAPs on colonic morphology as well as in improving symptoms of irritable bowel syndrome (IBS).
This mechanistic information, along with the clinical data, will allow planning of larger, multi-centre studies of the low FODMAP diet in similar patients.
HYPOTHESES
- Patients on a low FODMAP diet for 2 weeks will have a decreased fasting colonic volume measured by Magnetic Resonance Imaging (MRI) compared to participants who have not started the diet.
- Patients with IBS are more likely to report a clinically important improvement in symptoms following the low FODMAP diet (immediate intervention) compared to those on their habitual diet (delayed intervention).
PRIMARY OBJECTIVE • To compare the proportion of IBS patients reporting a clinically important improvement in symptoms following a low FODMAP diet for 2 weeks against IBS patients who are on their habitual diet.
SECONDARY OBJECTIVES
• Determine the difference in fasting colonic volume of IBS patients receiving low FODMAP dietary intervention after 2 weeks compared to those on habitual diet.
TRIAL DESIGN
This will be a pilot single-blind, randomised, controlled trial (RCT). Since some activity will take place on the University of Nottingham this will be a multi-centre study.
All participants will receive advice from a dietitian on the low FODMAP diet. They will be randomised to one of two parallel treatment arms:
- Low FODMAP dietary advice (immediate intervention)
- Habitual diet (control - delayed intervention )
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
- Nottingham Digestive Diseases Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 and above
- Able to give informed consent
- Previous Diagnosis of IBS by medical practitioner
- Meeting ROME III criteria for IBS
- Investigations showing negative tissue transglutaminase (tTG) IgA antibodies
- Full blood count test does not indicate Anaemia
Exclusion Criteria:
Inclusion
- Aged 18 and above
- Able to give informed consent
- Previous Diagnosis of IBS by medical practitioner
- Meeting ROME III criteria for IBS
- Investigations showing negative tissue transglutaminase (tTG) IgA antibodies
- Full blood count test does not indicate Anaemia
Exclusion
- Children (<18 years)
History declared by the candidate of pre-existing gastrointestinal disorder, including but not limited to:
- Inflammatory Bowel Disease
- Coeliac Disease
- Pancreatitis
- Gallstone disease (biliary colic, cholecystitis)
- Diverticulitis
- Cancer of the gastrointestinal tract
- Reported history of previous resection of any part of the gastrointestinal tract other than appendix or gallbladder
- Intestinal stoma
- Limited understanding of English
- Pregnancy declared by the candidate
- Red flag symptoms such as rectal bleeding, family history of bowel or ovarian cancer, a change in bowel habit to looser and/or more frequent stools persisting for more than six weeks in a person aged over 60 years.
- Investigations showing positive tissue transglutaminase (tTG) IgA antibodies
- Anaemia confirmed by full blood count test
- Habitual use of opiate analgesics likely to alter bowel function e.g. morphine
- Use of antibiotics in the preceding four weeks other than for treatment of index infection.
- Any condition where the candidate is likely to require a course of antibiotics in the next 3 months e.g. severe chronic respiratory disease, recurrent urinary tract infection, lower limb ulceration
- Inability to complete the symptom questionnaires e.g. cognitive dysfunction limiting memory and understanding
- Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g. chaotic lifestyle related to substance abuse
- Dietary practice not compatible with safe implementation of the trial diet e.g.veganism
- Medical reasons for pre-existing controlled diet that cannot be safely randomised e.g. end-stage kidney disease, diabetes
- Participants taking prebiotic/probiotic
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Immediate Intervention
Participants in this arm will receive an immediate low FODMAP dietary intervention on their second visit after they have been screened, consented and enrolled during visit 1.
|
Both arms will receive the intervention but at different time points.
|
Placebo Comparator: Delayed Intervention
Participants in this arm will receive a delayed Low FODMAP dietary intervention during their third visit after they have been been screened, consented and enrolled during visit 1.
|
Both arms will receive the intervention but at different time points.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adequate symptom relief between cases and controls
Time Frame: Assessed in cases on their last day of the intervention (2 weeks after dietary change). Assessed in controls before they began their intervention (between 1-2 weeks before dietary changes)
|
Adequate symptom relief assessed by questionnaire after intervention in cases and before intervention in cases
|
Assessed in cases on their last day of the intervention (2 weeks after dietary change). Assessed in controls before they began their intervention (between 1-2 weeks before dietary changes)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in colonic volume between cases and controls from baseline
Time Frame: Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
A change in colonic volume measured in milliliters (ml) from baseline and after intervention in cases.
This will compared with a change in colonic volume from baseline and before intervention in controls.
|
Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
Changes in fermentation between cases and controls
Time Frame: Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
A change in breath hydrogen concentration measured in parts per million (ppm) from: baseline and after intervention (cases) ii) from baseline and before intervention (controls)
|
Measured : i) baseline (day 0), ii) last day of intervention (cases) (2 weeks after dietary change), iii) before intervention (2 weeks before dietary advice)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15081
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
ClasadoCR2O B.V.RecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome - Constipation | Irritable Bowel Syndrome - Diarrhoea | Irritable Bowel Syndrome - MixedBelgium, Netherlands, United Kingdom
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
University of ViennaCompleted
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
Shahid Beheshti University of Medical SciencesCompletedIrritable Bowel DiseaseIran, Islamic Republic of
-
Universidad Autonoma de ChihuahuaNot yet recruitingIrritable Bowel Syndrome | Constipation-predominant Irritable Bowel Syndrome | Diarrhea- Irritable Bowel Syndrome
-
Vasily IsakovRussian Science Foundation; Azbuka vkusa; Federal Research Centre of Nutrition...CompletedIrritable Bowel Syndrome With Constipation | Constipation-predominant Irritable Bowel SyndromeRussian Federation
Clinical Trials on Low FODMAP Diet
-
Ashok TutejaUnited States Department of DefenseUnknown
-
Cantonal Hospital of St. GallenCompletedIBS - Irritable Bowel Syndrome
-
Beth Israel Deaconess Medical CenterEnrolling by invitation
-
Ohio State UniversityCompletedAutism Spectrum DisorderUnited States
-
Taipei Veterans General Hospital, TaiwanNot yet recruitingIrritable Bowel Syndrome
-
Oslo University HospitalActive, not recruitingIrritable Bowel Syndrome | Diet Modification | Celiac Disease | Gluten SensitivityNorway
-
Northwestern UniversityWithdrawn
-
Medical University of WarsawNutricia FoundationUnknown
-
Hospital General de MexicoUnknownIBS - Irritable Bowel Syndrome | UC - Ulcerative Colitis | IBD - Inflammatory Bowel DiseaseMexico
-
University of AarhusCompletedIrritable Bowel Syndrome | Endometriosis | Visceral Syndrome | Visceral HypersensitivityDenmark